ZHONGZHIPHARM (03737) announced its financial results for the six months ended June 30, 2025, reporting revenue of RMB 880 million, representing a year-on-year decrease of 19.1%. Profit attributable to owners of the parent company reached RMB 8.783 million, marking a significant decline of 89.5% compared to the same period last year. Basic earnings per share stood at RMB 0.010.